Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic

Covid19 Clinical Trial

— COVIE-19/20  

Official title:

Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04487171
• Other study ID #: PI2020_843_0049
• Status: Recruiting
• Phase: N/A
• Start date: July 21, 2020
• Est. completion date: August 2023

Study information

• Verified date: March 2023
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: Arthur FOULON, MD
• Phone: (33)322087382
• Email: foulon.arthur[@]chu-amiens.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Postpartum depression (PPD) represent around 15% of birth in developed countries. The context of the COVID-19 epidemy represents a possible source of additional emotional distress. The objective of this study is to determine the screening prevalence and risk factors of postpartum depression, among women who deliver in fourth hospital in the North of France in the context of the COVID epidemy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 248
• Est. completion date: August 2023
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Single baby delivery
• alive new born child without admission in neonatal intensive care unit
• French-speaking mother
• mother older than 18 years old

Exclusion Criteria:

• Patients who refuses the inclusion

Related Conditions & MeSH terms

• COVID-19
• Covid19
• Depression
• Depression, Postpartum
• Depressive Disorder
• Postpartum Depression
• Prevalence
• Social Distance

Intervention

Other:
• Questionnaire
The mothers were administrated three questionnaires, (i) the Edinburgh Postnatal Depression Scale (EPDS), (ii) the State-Trait Anxiety Inventory (STAI-YA), and (iii) the Mother-to-Infant Bonding Scale (MIBS) in two stages, on days 2-3 after delivery and during a phone call between days 25-35.

Locations

Country	Name	City	State
France	CHU Amiens	Amiens

Sponsors (4)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens	Central Hospital Saint Quentin, Centre Hospitalier Compiègne, Centre Hospitalier de Beauvais

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Variation of prevalence of clinically-significant post-partum depressive symptoms	Variation of prevalence of clinically-significant post-partum depressive symptoms	up to 35 days after delivery